Global Biologics Market Overview:
Global Biologics Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2026-2035, Considering the Base Year As 2025.
Global Biologics Market Report 2026 comes with the extensive industry analysis with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2026-2035, with base year as 2025. This research study of Biologics involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Biologics Market:
The Biologics Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Biologics Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Biologics Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Biologics market has been segmented into:
Infectious Diseases
Oncology
Autoimmune Diseases
Diabetes
Other Applications
By Application, Biologics market has been segmented into:
Recombinant Therapeutic Proteins
Blood & Blood components
Cellular & Gene Therapy
Vaccines).
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Biologics market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Biologics market.
Top Key Players Covered in Biologics market are:
AbbVie Inc.
Amgen Inc.
AstraZeneca PLC
Bristol-Myers Squibb Company
Celgene Corporation
Eli Lilly and Company
GlaxoSmithKline PLC
Janssen Pharmaceuticals Inc.
Merck & Co. Inc.
Novartis AG
Novo Nordisk A/S
Pfizer Inc.
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: Biologics Market Type
4.1 Biologics Market Snapshot and Growth Engine
4.2 Biologics Market Overview
4.3 Infectious Diseases
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.3.3 Infectious Diseases: Geographic Segmentation Analysis
4.4 Oncology
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.4.3 Oncology: Geographic Segmentation Analysis
4.5 Autoimmune Diseases
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.5.3 Autoimmune Diseases: Geographic Segmentation Analysis
4.6 Diabetes
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.6.3 Diabetes: Geographic Segmentation Analysis
4.7 Other Applications
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.7.3 Other Applications: Geographic Segmentation Analysis
Chapter 5: Biologics Market Application
5.1 Biologics Market Snapshot and Growth Engine
5.2 Biologics Market Overview
5.3 Recombinant Therapeutic Proteins
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.3.3 Recombinant Therapeutic Proteins: Geographic Segmentation Analysis
5.4 Blood & Blood components
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.4.3 Blood & Blood components: Geographic Segmentation Analysis
5.5 Cellular & Gene Therapy
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.5.3 Cellular & Gene Therapy: Geographic Segmentation Analysis
5.6 Vaccines).
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.6.3 Vaccines).: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Biologics Market Share by Manufacturer (2025)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 ABBVIE
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.3 INC.; AMGEN
6.4 INC.; ASTRAZENECA PLC; BRISTOL-MYERS SQUIBB COMPANY; CELGENE CORPORATION; ELI LILLY AND COMPANY; GLAXOSMITHKLINE PLC; JANSSEN PHARMACEUTICALS
6.5 INC.; MERCK & CO.
6.6 INC.; NOVARTIS AG; NOVO NORDISK A/S; PFIZER
6.7 INC.
Chapter 7: Global Biologics Market By Region
7.1 Overview
7.2. North America Biologics Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 Infectious Diseases
7.2.2.2 Oncology
7.2.2.3 Autoimmune Diseases
7.2.2.4 Diabetes
7.2.2.5 Other Applications
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1 Recombinant Therapeutic Proteins
7.2.3.2 Blood & Blood components
7.2.3.3 Cellular & Gene Therapy
7.2.3.4 Vaccines).
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe Biologics Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 Infectious Diseases
7.3.2.2 Oncology
7.3.2.3 Autoimmune Diseases
7.3.2.4 Diabetes
7.3.2.5 Other Applications
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1 Recombinant Therapeutic Proteins
7.3.3.2 Blood & Blood components
7.3.3.3 Cellular & Gene Therapy
7.3.3.4 Vaccines).
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe Biologics Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 Infectious Diseases
7.4.2.2 Oncology
7.4.2.3 Autoimmune Diseases
7.4.2.4 Diabetes
7.4.2.5 Other Applications
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1 Recombinant Therapeutic Proteins
7.4.3.2 Blood & Blood components
7.4.3.3 Cellular & Gene Therapy
7.4.3.4 Vaccines).
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific Biologics Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 Infectious Diseases
7.5.2.2 Oncology
7.5.2.3 Autoimmune Diseases
7.5.2.4 Diabetes
7.5.2.5 Other Applications
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1 Recombinant Therapeutic Proteins
7.5.3.2 Blood & Blood components
7.5.3.3 Cellular & Gene Therapy
7.5.3.4 Vaccines).
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa Biologics Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 Infectious Diseases
7.6.2.2 Oncology
7.6.2.3 Autoimmune Diseases
7.6.2.4 Diabetes
7.6.2.5 Other Applications
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1 Recombinant Therapeutic Proteins
7.6.3.2 Blood & Blood components
7.6.3.3 Cellular & Gene Therapy
7.6.3.4 Vaccines).
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America Biologics Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 Infectious Diseases
7.7.2.2 Oncology
7.7.2.3 Autoimmune Diseases
7.7.2.4 Diabetes
7.7.2.5 Other Applications
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1 Recombinant Therapeutic Proteins
7.7.3.2 Blood & Blood components
7.7.3.3 Cellular & Gene Therapy
7.7.3.4 Vaccines).
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Biologics Scope:
|
Report Data
|
Biologics Market
|
|
Biologics Market Size in 2025
|
USD XX million
|
|
Biologics CAGR 2025 - 2032
|
XX%
|
|
Biologics Base Year
|
2024
|
|
Biologics Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, GlaxoSmithKline PLC, Janssen Pharmaceuticals Inc., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc..
|
|
Key Segments
|
By Type
Infectious Diseases
Oncology
Autoimmune Diseases
Diabetes
Other Applications
By Applications
Recombinant Therapeutic Proteins
Blood & Blood components
Cellular & Gene Therapy
Vaccines).
|
